



Thursday, October 26, 2006

9:30 – 11:00 Redefining Treatment Expectations in Moderate-to-Severe Psoriasis

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

Session Objectives:

Dermatologists participating in this symposium will:

- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion

Faculty:

Dr. Kim Papp, Chair
Dr. Brian Feagan
Dr. Kristian Reich
Dr. Kam Shojania
Dr. Norman Wasel

Agenda:

| | | |
|-------------------|--|----------------------|
| 9:30am – 9:35am | Welcome | Kim Papp, MD – Chair |
| 9:35am – 10:00am | The Use of TNF Blockers in Chronic Inflammatory Disease: What are the Important Safety Issues? | Brian Feagan, MD |
| 10:00am – 10:15am | Changing Paradigms in Moderate-to-Severe Psoriasis | Norman Wasel, MD |
| 10:15am – 10:40am | Unmet Needs of Psoriasis and the Promise of Biologics | Kristian Reich, MD |
| 10:40am – 10:55am | Remicade Infusion Network: Experience in the Rheumatology Community | Kam Shojania, MD |
| 10:55am – 11:00am | Closing Remarks | Kim Papp, MD - Chair |

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Thursday, October 26, 2006

2:00 – 3:30 From Trial to Clinic: A Year of Raptiva Experience in Canada

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

Session Objectives:

Following this workshop, the attendee will be able to:

- Define the appropriate patients for biological agents
- Apply practical considerations in the use of biologics for the treatment of psoriasis, with a focus on Raptiva
- Review the efficacy and safety of Raptiva as observed in Canadian clinical practice

Faculty:

1. Charles Lynde, MD FRCPC – Chair/Moderator, Intro & Close
2. Richard Langley MC FRCPC – Raptiva: Suitable for a Wide Range of Psoriasis Patients
3. Norm Wasel, MD FRCPC – Clinical Cases With Raptiva (Canadian Perspective)
4. Kim Papp, MD PhD FRCPC – Expert Panel Discussion

Program:

Clinical use of biologic therapies is changing the way dermatologists are treating moderate-to-severe psoriasis. As physicians gain experience with these agents, they are learning practical tips on which agents are best for which patients and why, and on how to optimally use each agent. This program is directed to the practicing dermatologist who treats patients with moderate to severe psoriasis. Topics covered will discuss:

- ✓ How to select an appropriate agent for a patient (with a focus on selecting patients appropriate for treatment with Raptiva) – based on different patient profiles
- ✓ Practical guidelines for treating patients with Raptiva, using Canadian case histories.

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Thursday, October 26, 2006

| | | |
|--------------------|--|----------------------------------|
| 4:00 – 5:45 | Plenary Session 1 | Chair: Dr. Richard Thomas |
| | <i>Room: Macdonald ABCD, Fairmont Chateau Whistler Resort</i> | |
| 4:00 – 4:05 | Opening Remarks | Dr. Richard Thomas |
| 4:05 – 4:25 | Update on Topical Therapies of Psoriasis | Dr. John Koo |
| 4:25 – 4:45 | Efalizumab for Patients with Palmoplantar Psoriasis | Dr. Richard Langley |
| 4:45 – 5:05 | Adalimumab in Psoriasis: CHAMPION Phase III Trial Results | Dr. Richard Langley |
| 5:05 – 5:25 | Cosmeceutical Advances – the Latest Approaches to Decrease Unwanted Pigmentation | Dr. Alexa Kimball |
| 5:25 – 5:45 | Panel and Questions | |

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Friday, October 27, 2006

9:30 – 11:00 New Advances in Photobiology and Photoprotection

Room: Frontenac C, Fairmont Chateau Whistler Resort

Session Objectives:

Dermatologists participating in this symposium will :

- have an update of the skin damages caused by UVA radiation
- recognize the importance of UVA protection and the need for sunscreens with broad spectrum UVA/UVB protection
- acquire knowledge of UVA protection evaluation with PPD (Persistent Pigment Darkening) method
- evaluate the efficacy of different sunscreens formulations and the benefits of the new filter Mexoryl XL

Faculty:

Dr Jason Rivers , Chair

Dr Robert Bissonnette

Anny Fourtanier, L'Oreal Recherche

Dominique Moyal, L'Oreal Recherche

Jean Louis Refregier, L'Oreal Recherche

Agenda:

ULTRAVIOLET RADIATION: PUBLIC HEALTH CONCERNS.

J.K. Rivers –Department of Dermatology, University of British Columbia, Vancouver

UPDATE ON UVA INDUCED SKIN PHOTODAMAGE

A. Fourtanier -L'Oréal Recherche, Clichy, France

IMPORTANCE OF UVA PROTECTION: SKIN CANCER AND BEYOND.

R. Bissonnette MD, FRCPC Innovaderm Research, Montreal

UVA PHOTOPROTECTION EVALUATION

D. Moyal, L'Oréal Recherche, France

NEW ADVANCES IN SUN CARE PRODUCTS: IMPROVED UVA PROTECTION WITH MEXORYL XL

J.L. Refregier, Development Director for Sun Care Products, International Applied and Development Research, L'Oreal

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Friday, October 27, 2006

11:30 – 1:30 **Biologics and Psoriatic Disease: Practical Management Issues and Clinical Update**

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

Session Objectives:

Dermatologists participating in this symposium will;

- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion

Faculty:

Richard Thomas, MD (Vancouver, British Columbia)
Joseph Jorizzo, MD (Winston-Salem, North Carolina)
Richard Langley, MD (Halifax, Nova Scotia)

Agenda:

| | | |
|-------|---|---------------------|
| 11:30 | Introduction, Learning Objectives, Pre-Assessment (touchpads) | Richard Thomas, MD |
| 11:40 | Biologics: Practical Management Issues (US Experience) | Joseph Jorizzo, MD |
| 12:20 | Safety Update: TNF Antagonists | Richard Langley, MD |
| 13:00 | Panel Discussion | |
| 13:25 | Post-Assessment and Closing Remarks | |
| 13:30 | Adjourn | |

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Friday, October 27, 2006

4:00 – 5:40 Plenary Session 2 Chair: Dr. Chuck Lynde
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

4:00 – 4:20 Objectives for Dermatological Toxicities of
anti-EGFR Therapies in Cancer Dr. Mario Lacouture

4:20 – 4:40 New Aspects in the pathophysiology and
Treatment of Psoriatic Arthritis Dr. Kristian Reich

4:40 – 5:00 Pyoderma Gangrenosum and its
Management in 2006 Dr. Joseph L. Jorizzo

5:00 – 5:20 Facial Pigmented Lesions:
Diagnosis and Treatment Dr. Joël Claveau

5:20 – 5:40 Effects of UVB and UVA on Human Skin
Pigmentation and Prevention by Sunscreens Dr. Dominique Moyal

5:40 – 6:00 Panel and Questions

6:00 – 7:30 *Cocktail Reception*

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Saturday, October 28, 2006

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

7:00 – 8:30 *Buffet Breakfast*

8:30 – 9:00 **Plenary Session 3**

Chair: Dr. Harvey Lui

8:30 – 9:00 Skin Therapy Update

Dr. Stuart Maddin

9:00 – 9:20 The Global Regulatory Village –
Helpful or Harmful to Patients and Physicians

Dr. Gavin Corcoran

9:20 – 9:30 Panel and Questions

9:30 – 9:55 *Coffee Breaks and Poster Exhibits*

10:00 – 11:25 **The Impact of Advocacy on Dermatologists and their Patients**

10:00 – 10:05 Opening Remarks

Dr. Harvey Lui - Chair

10:05 – 10:55 The Need for Advocacy (*interactive*)

Dr. Albert Schumacher

10:55 – 11:05 Canadian Skin Patient Alliance:
Progress Report

Mr. Denis Morrice

11:05 – 11:15 Industry – Advocacy:
Impact on Access to Treatment

11:30 – 1:30 *Boxed Lunch provided for participants not attending advisory board meetings*

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Saturday, October 28, 2006

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

2:00 – 3:20 Plenary Session 4 Chair: Dr. Jerry Tan

2:00 – 2:20 The Management of Hair Disorders
in Women: Too Much – Too Little Dr. Jerry Shapiro

2:20 – 2:40 Topical Calcineurin Inhibitors –
Where Do We Stand Dr. Alan Fleischer

2:40 – 3:00 Elidel EADV 2006 Update Dr. Kirk Barber

3:00 – 3:20 Panel and Questions

3:20 – 3:45 *Coffee Breaks and Poster Exhibits*

3:45 – 4:20 Plenary Session 5 Chair: Dr. Jan Dutz

3:20 – 3:40 “Dead Lice Don’t Lay Eggs” - A Product
Development Story Dr. Bill Campbell

3:40 – 4:00 The Skin as a site of initiation of systemic
Autoimmune disease: new opportunities for
Treatment Dr. Jan Dutz

4:00 – 4:15 Panel and Questions

4:15 – 4:25 Closing Comments Dr. Stuart Maddin

4:30 – 6:30 *Closing Reception*
Room: Frontenac Ballroom, Fairmont Chateau Whistler Resort

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.



Sunday, October 29 2006

8:30 – 11:00 Clinical Trial Workshop: Optimizing Your Research Site
Room: Macdonald E, Fairmont Chateau Whistler Resort
(pre-registration required, FEE: \$150+gst)

Directed by:

Lynne Bulger, Director Medical Affairs, Barrier Therapeutics
Paul Kidson, Director Medical Affairs, LEO Pharma

Topics:

1. Site Selection: The CRO Perspective
Doug Keller, President, Moncoa Medical Research Inc.

Site Selection: The Industry Perspective
Todd Georgieff, Senior Manager, Clinical Operations, Abbott
Lynne Bulger, Director Medical Affairs, Barrier
2. Multidisciplinary Co-operation: Dermatology and Rheumatology
Richard Thomas
3. Keeping Up With the Times: Remote Data Capture
Paul Kidson
4. Spreading the Good News: Master Plan for Site Metrics
Lynne Bulger and Paul Kidson

October 25-29, 2006
Fairmont Chateau Whistler, Whistler, B.C.